DengiAll

DengiAll Latest News

India has reached the 50 per cent enrolment mark in its first phase III clinical trial for the indigenous tetravalent dengue vaccine, DengiAll.

About DengiAll

• It is developed by Panacea Biotec Limited under a licensing agreement with the National Institutes of Health (NIH).
• has a weakened form of all four dengue virus subtypes and has the same virus composition as the vaccine developed by NIH, except for the inactive ingredients. 
• A Phase I and II clinical trial conducted in India revealed a balanced and robust immune response across all four dengue virus types. The vaccine was also found to be safe and well-tolerated.
• Multiple ICMR institutes are involved in the study to evaluate the efficacy, immunogenicity and safety of DengiAll. The ICMR-National Institute of Translational Virology (NITVAR) and AIDS Research (formerly ICMR-NARI) is responsible for overall trial coordination.

Key Facts about Dengue

• It is a mosquito-borne viral infection.
• It is more common in tropical and subtropical climates, mostly in urban and semi-urban areas.

Transmission of Dengue

• It is transmitted to humans through the bite of infected Aedes mosquitos carrying one of four types of dengue virus (DENV).
• Dengue isn’t contagious from person to person except when passed from a pregnant person to their child.

Symptoms of Dengue

• The most common symptoms are high fever, headache, body aches, nausea, and rash. Most will get better in 1–2 weeks.
• A very small portion of people with dengue fever get a severe case. It’s called dengue hemorrhagic fever.
• Treatment: There is no specific medicine to treat dengue. The focus is on treating pain symptoms.

Source: IE

‹ ›